source
- Delix raises $100M to advance at-home psychedelic without hallucinogenic effectsThe series C raise, co-led by Johnson & Johnson’s venture capital arm, will help Delix Therapeutics push its novel psychedelic asset into mid-stage development for major depressive disorder.BioSpace · 10d ago↗ source
- Recon: Bayer wins FDA approval for stroke prevention drug; Third Rock enters $2B partnership with AI-focused Chinese biotechWelcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.raps · 11d ago↗ source
- FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High RiskFDA today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a rec…